Pharmaceuticals News and Research

RSS

IDEXX Laboratories fourth quarter revenues increase 5% to $283.8 million

IDEXX Laboratories, Inc., today reported that revenues for the fourth quarter of 2010 increased 5% to $283.8 million, from $270.3 million for the fourth quarter of 2009. Organic revenue growth, as defined below, was 6%. Earnings per diluted share ("EPS") for the quarter ended December 31, 2010 increased 22% to $0.62, compared to $0.51 for the same period in the prior year.

28 Jan 2011

DSM supports Queensland Premier's 'Disaster Relief Appeal'

Significant flooding occurred in many areas of Queensland during late December 2010 and early January 2011. Thousands of residents were affected. A disaster relief appeal, the 'Premier's Disaster Relief Appeal', was launched on 29 December 2010, by Premier of Queensland, Anna Bligh. DSM recognizes the efforts of Queenslanders who pitched in to help their fellow citizens clean-up in the wake of the floods and help families in need, many of whom lost everything.

28 Jan 2011

Taro fourth quarter net sales increase 22.7% to $102.2 million

Taro Pharmaceutical Industries Ltd. today provided preliminary, unaudited and unreviewed financial results for the quarter and year ended December 31, 2010.

28 Jan 2011

Misaligned research, medical challenges and harsh economics thwart efforts against Alzheimer's disease

Misaligned research, medical challenges and harsh economics are thwarting efforts to slow the destructive course of Alzheimer's disease in the United States, according to a trio of nationally regarded Alzheimer's researchers writing a "Perspective" in Jan. 27 issue of the journal Neuron.

28 Jan 2011

EHSI examines business plans and product lines of OceanBASIS

Emerging Healthcare Solutions, Inc. is examining the business plans and product lines of German biotech firm OceanBASIS as part of the company's due diligence towards a potential profit sharing agreement.

28 Jan 2011

Tarceva Phase III EURTAC study in NSCLC patients with EGFR activating mutations meets primary endpoint

Genentech, a member of the Roche Group and OSI Pharmaceuticals, a wholly owned subsidiary of Astellas U.S. Holding Inc., a holding company owned by Astellas Pharma Inc., today announced that an independent data monitoring committee has recommended that the Phase III EURTAC study be stopped early because the study met its primary endpoint.

28 Jan 2011

Cetero Research completes 20,000th early-phase clinical study

Cetero Research, the leading early-stage contract research organization, today announced that it has reached another industry milestone with the completion of its 20,000th early-phase clinical study.

28 Jan 2011

Bioniche Life Sciences joins Australian Securities Exchange

Bioniche Life Sciences Inc., a research-based, technology-driven Canadian biopharmaceutical company, today announced that it has joined the official list of the Australian Securities Exchange (ASX) and its securities are now trading on that exchange under the code "BNC".

28 Jan 2011

Arena reduces workforce by 25% and provides update on lorcaserin

Arena Pharmaceuticals, Inc. announced today a reduction of its US workforce of approximately 25%, or 66 employees. As a result of the workforce reduction, which Arena plans to complete around March 28, 2011, the company expects to incur restructuring charges, primarily in the first quarter of 2011, of approximately $3.8 million in connection with one-time employee termination costs.

28 Jan 2011

Preclinical data on Inovio’s intradermal electroporation delivery devices presented at Phacilitate Vaccine Forum

Inovio Pharmaceuticals, Inc., a leader in the development of novel therapeutic and preventive vaccines against cancers and infectious diseases, announced today the presentation of recent preclinical data using its next generation of minimally invasive intradermal (skin) electroporation delivery devices at the Phacilitate Vaccine Forum 2011 in Washington, DC.

28 Jan 2011

Inovio to use proceeds from $24.3M offering for development of DNA vaccine against cervical dysplasias

Inovio Pharmaceuticals, Inc., a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today the closing of the sale to a single institutional investor of 21,130,400 shares of its common stock and warrants to purchase up to 10,565,200 additional shares of its common stock.

28 Jan 2011

USPTO issues Notice of Allowances to Lakewood's three patent applications for treatment of HUS

Lakewood-Amedex, a leading developer of novel anti-infective pharmaceuticals, announced today that the United States Patent and Trademark Office has issued Notice of Allowances on three patent applications relating to the use of novel monoclonal antibodies for the treatment of hemolytic uremic syndrome caused by shiga toxin II secreting E.coli O157: H7 strain.

28 Jan 2011

Soligenix and CU enter definitive license agreement for novel vaccine thermostabilization technology

Soligenix, Inc., a late-stage biopharmaceutical company, today announced that it has entered into a definitive license agreement with the University of Colorado (CU) for novel technology for use in the development of subunit vaccines with long-term stability, including stability at elevated temperatures.

28 Jan 2011

Endo and Orion enter oncology R&D collaboration

Endo Pharmaceuticals announced today that it has entered into a collaboration agreement with European-based Orion Corporation for the discovery, development and commercialization of assets in Oncology.

28 Jan 2011

Tibotec grants multiple non-exclusive licenses to generic manufacturers for rilpivirine hydrochloride

Tibotec Pharmaceuticals today announced that it has granted multiple non-exclusive licenses to generic manufacturers including Hetero Drugs Limited, Matrix Laboratories Limited (a Mylan company) of India and Aspen Pharmacare of South Africa to manufacture, market and distribute the investigational non-nucleoside reverse transcriptase inhibitor rilpivirine hydrochloride (TMC278), pending its approval for use with other antiretroviral agents in the treatment of treatment-naive HIV-1 infected adults.

28 Jan 2011

Matrix enters licensing agreement with Tibotec for generic Rilpivirine Hydrochloride

Mylan Inc. today announced that its subsidiary Matrix Laboratories Limited has signed an agreement with Tibotec Pharmaceuticals for a non-exclusive license to manufacture, market and distribute a generic version of the non-nucleoside reverse transcriptase inhibitor Rilpivirine Hydrochloride (TMC278), pending its regulatory approval for the treatment of treatment-naive HIV-1-infected adults.

28 Jan 2011

Interim results from ganetespib Phase 2 trial in NSCLC to be presented at 11th IASLC annual meeting

Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that Dr. Jonathan Goldman, M.D., Premiere Oncology will present interim results from a Phase 2 trial of ganetespib in non-small cell lung cancer at the International Association for the Study of Lung Cancer 11th Annual Targeted Therapies for the Treatment of Lung Cancer Meeting.

28 Jan 2011

Positive results from RXi's sd-rxRNA technology for development of novel therapeutics

RXi Pharmaceuticals Corporation, a recognized leader in RNAi-based therapeutics, announced today that, as part of its collaboration with miRagen Therapeutics, positive data were generated demonstrating that RXi's sd-rxRNA technology can be used, in vitro, to specifically enhance the activity of a microRNA of high interest to miRagen.

28 Jan 2011

Pfizer announces termination of HSR waiting period for acquisition of King

Pfizer Inc. today announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR Act) has been terminated in connection with the tender offer by its wholly-owned subsidiary, Parker Tennessee Corp., to purchase all outstanding shares of common stock of King Pharmaceuticals, Inc. for $14.25 per share, net to the seller in cash, without interest thereon and subject to any required withholding taxes.

27 Jan 2011

Provectus announces completion of PV-10 Phase 1 trial in patients with liver cancer

Provectus Pharmaceuticals, a development-stage oncology and dermatology biopharmaceutical company, has completed patient accrual and treatment of all subjects in its Phase 1 clinical trial of PV-10 for liver cancer.

27 Jan 2011

Pharmaceuticals News and Research

IDEXX Laboratories fourth quarter revenues increase 5% to $283.8 million

DSM supports Queensland Premier's 'Disaster Relief Appeal'

Taro fourth quarter net sales increase 22.7% to $102.2 million

Misaligned research, medical challenges and harsh economics thwart efforts against Alzheimer's disease

EHSI examines business plans and product lines of OceanBASIS

Tarceva Phase III EURTAC study in NSCLC patients with EGFR activating mutations meets primary endpoint

Cetero Research completes 20,000th early-phase clinical study

Bioniche Life Sciences joins Australian Securities Exchange

Arena reduces workforce by 25% and provides update on lorcaserin

Preclinical data on Inovio’s intradermal electroporation delivery devices presented at Phacilitate Vaccine Forum

Inovio to use proceeds from $24.3M offering for development of DNA vaccine against cervical dysplasias

USPTO issues Notice of Allowances to Lakewood's three patent applications for treatment of HUS

Soligenix and CU enter definitive license agreement for novel vaccine thermostabilization technology

Endo and Orion enter oncology R&D collaboration

Tibotec grants multiple non-exclusive licenses to generic manufacturers for rilpivirine hydrochloride

Matrix enters licensing agreement with Tibotec for generic Rilpivirine Hydrochloride

Interim results from ganetespib Phase 2 trial in NSCLC to be presented at 11th IASLC annual meeting

Positive results from RXi's sd-rxRNA technology for development of novel therapeutics

Pfizer announces termination of HSR waiting period for acquisition of King

Provectus announces completion of PV-10 Phase 1 trial in patients with liver cancer

Event guide: World ADC San Diego eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence